Home » Market News » DirectorsTalk Highlights » Rare and Once-ignored Mutations May Contribute to Lupus, Study Finds
Immupharma Plc

Rare and Once-ignored Mutations May Contribute to Lupus, Study Finds

Certain rare gene mutations, previously ignored, appear to contribute substantially to the development of lupus, new research found, pointing to the potential for targeted therapies for the condition.

The study, “Functional rare and low frequency variants in BLK and BANK1 contribute to human lupus,” was published in Nature Communications.

The cause of lupus has long been a mystery. It’s assumed to be due to some combination of environmental and genetic factors, but figuring out precisely what those factors are has proved a challenge.

Few AIM-listed drug development companies have late-stage clinical assets in the pipeline, ImmuPharma plc (LON:IMM) is an exception. The Company’s lead compound, Lupuzor™, a potential treatment for Lupus, has completed Phase 3 trial of dosing patients across the US, Europe and Mauritius with top line results announced.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.